Abstract | AIMS: METHODS: We conducted an openlabel trial, in Canada and the United States, of rituximab in 6 adult patients with Type I MPGN (4 idiopathic, 2 with cryoglobulinemia). The rituximab dose was 1,000 mg intravenously on Day 1 and on Day 15. The patients were followed for 1 year. The primary outcome was the change in proteinuria. RESULTS: Peripheral blood B cells were suppressed, after rituximab, in all patients. The mean urinary protein excretion was 3.9 ± 2.0 g/d before treatment. Proteinuria fell in all patients, at all-time points, after rituximab administration. The difference was statistically significant (p < 0.05) at 6, 9 and 12 months, but not at 3 months. The minimum mean urinary protein excretion was 1.4 ± 1.4 g/ d at 9 months. There were 2 complete and 3 partial remissions among the 6 patients. The creatinine clearance did not change significantly over the course of the study. There were no adverse effects. CONCLUSIONS:
Rituximab reduced proteinuria among patients with Type I MPGN. This trial suggests that B cells may play a role in this disease and that additional study of B-cell suppression is warranted.
|
Authors | John J Dillon, Michelle Hladunewich, William E Haley, Heather N Reich, Daniel C Cattran, Fernando C Fervenza |
Journal | Clinical nephrology
(Clin Nephrol)
Vol. 77
Issue 4
Pg. 290-5
(Apr 2012)
ISSN: 0301-0430 [Print] Germany |
PMID | 22445472
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Immunologic Factors
- Rituximab
|
Topics |
- Adult
- Aged
- Algorithms
- Antibodies, Monoclonal, Murine-Derived
(therapeutic use)
- Canada
- Cryoglobulinemia
(drug therapy)
- Female
- Glomerulonephritis, Membranoproliferative
(drug therapy, immunology)
- Humans
- Immunologic Factors
(therapeutic use)
- Injections, Intravenous
- Male
- Middle Aged
- Prognosis
- Proteinuria
(drug therapy)
- Rituximab
- Treatment Outcome
- United States
|